Mayo Clinic: Ovarian Neoplasms trials

The registry lists 22 Ovarian Neoplasms studies with Mayo Clinic as lead sponsor. 4 are open to participants now and 6 have results posted.

Early Phase 1 4Phase 1 7Phase 2 8No phase 5(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• The Cancer Connected Access and Remote Expertise Beyond Walls Program to Provide In-Home Cancer Treatment and Improve Treatment Satisfaction in Cancer Patients Living in the Florida Panhandle and Surrounding AreasRecruitingNCT07285044Phase 2
• Ultrasound Microvessel Imaging for the Evaluation of Ovarian and Adnexal LesionsRecruitingNCT07280312Not applicable
• MUC1-Activated T Cells for the Treatment of Relapsed and Resistant Ovarian CancerRecruitingNCT06483048Phase 1
• Leveraging Methylated DNA Markers (MDMs) in the Detection of Endometrial Cancer, Ovarian Cancer, and Cervical CancerRecruitingNCT05051722
• MV-NIS or Investigator's Choice Chemotherapy in Treating Patients With Ovarian, Fallopian, or Peritoneal CancerTerminatedNCT02364713Phase 2Results posted
• Avatar-Directed Chemotherapy in Treating Patients With Ovarian, Primary Peritoneal, or Fallopian Tube CancerCompletedNCT02312245Phase 2Results posted
• Everolimus and Letrozole in Treating Patients With Recurrent Hormone Receptor Positive Ovarian, Fallopian Tube, or Primary Peritoneal Cavity CancerCompletedNCT02283658Phase 2Results posted
• MV-NIS Infected Mesenchymal Stem Cells in Treating Recurrent Ovarian, Primary Peritoneal or Fallopian Tube CancerActive, not recruitingNCT02068794Phase 1/2Results posted
• Intra-op Detection of Occult Ovarian Carcinoma Using a Folate-Alpha Receptor Specific Fluorescent LigandTerminatedNCT01511055Phase 2Results posted
• Recombinant Measles Virus Vaccine Therapy and Oncolytic Virus Therapy in Treating Patients With Progressive, Recurrent, or Refractory Ovarian Epithelial Cancer or Primary Peritoneal CancerCompletedNCT00408590Phase 1Results posted
• Feasibility of Saliva and Remote Monitoring of Active Cytomegalovirus (CMV) Infection and Symptoms During Ovarian Cancer TreatmentCompletedNCT06870539
• Vaccine Therapy Plus Pembrolizumab in Treating Advanced Ovarian, Fallopian Tube, or Primary Peritoneal Cavity CancerActive, not recruitingNCT05920798Phase 1/2
• PLX038 for Treatment of Metastatic Platinum-resistant Ovarian, Primary Peritoneal, and Fallopian Tube CancerActive, not recruitingNCT05465941Phase 2
• Prehabilitation for Stage IIIC-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer PatientsCompletedNCT05047926Not applicable
• Metabolite Levels in Ovarian Cancer Patients Receiving Maintenance PARP InhibitorsCompletedNCT04917744
• Heated Intra-peritoneal Chemotherapy with Doxorubicin and Cisplatin for Abdominal for Pelvic Tumors in Pediatric PatientsTerminatedNCT04213794Early Phase 1
• Pharmacogenomics Testing in the Optimal Use of Supportive Care Medications in Stage III-IV CancerCompletedNCT04067960Early Phase 1
• Nanoparticle Albumin-Bound Rapamycin in Treating Patients With Advanced Cancer With mTOR MutationsCompletedNCT02646319Early Phase 1
• Vaccine Therapy for Patients With Stage IIIC-IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity CancerCompletedNCT02111941Early Phase 1
• Nab-Paclitaxel and Bevacizumab in Treating Patients With Unresectable Stage IV Melanoma or Gynecological CancersCompletedNCT02020707Phase 1
• Vaccine Therapy and Cyclophosphamide in Treating Patients With Stage II-III Breast or Stage II-IV Ovarian, Primary Peritoneal, or Fallopian Tube CancerCompletedNCT01606241Phase 1
• Topotecan, High-Dose Cyclophosphamide, Carboplatin, and an Autologous Peripheral Blood Cell Transplant in Treating Patients With Recurrent Ovarian Cancer or Primary Peritoneal CancerCompletedNCT00652691Phase 1